VERV Live signals | Maximize Profits with Getagraph.com

SELL 94158 min ago

@ $12.71

Issued: 14 Feb 2024 @ 14:22

Return: -47.76%

Previous signal: Feb 14 - 12:04

Previous signal: Buy

Return: 0.87 %

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	1.06M
Average Volume	1.29M
Market Cap	521.57M
EPS	$0 ( 2024-03-07 )
Next earnings date	( $-0.680 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.13
ATR14	$0.0130 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Nickerson Joan	Buy	3 315	Common Stock
2024-04-01	Nickerson Joan	Sell	3 315	Restricted Stock Units
2024-04-02	Nickerson Joan	Sell	1 514	Common Stock
2024-02-14	Ashe Andrew D.	Buy	150 000	Stock Option (right to buy)
2024-02-14	Ashe Andrew D.	Buy	36 000	Restricted Stock Units

INSIDER POWER
78.14
Last 97 transactions
Buy: 4 843 517 \| Sell: 1 394 833

Volume Correlation

Long: 0.49 (neutral)

Short: 0.09 (neutral)

Signal:(69.539) Neutral

Verve Therapeutics, Inc. Correlation

10 Most Positive Correlations
SVOK	0.939
BIOL	0.915
ARVN	0.9
TSP	0.886
TIL	0.885
UK	0.884
YMAB	0.88
AVCT	0.879
FCACU	0.874
TFFP	0.873

10 Most Negative Correlations
BOCH	-0.93
SHSP	-0.897
LMRK	-0.881
QADA	-0.877
VLYPO	-0.863
RAVN	-0.852
NETE	-0.84
MMSI	-0.837
NRIM	-0.836
MDLZ	-0.83

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Verve Therapeutics, Inc. Correlation - Currency/Commodity

-0.77
( moderate negative )

-0.90
( strong negative )

0.00
( neutral )

-0.35
( neutral )

-0.26
( neutral )

0.36
( neutral )

Verve Therapeutics, Inc. Financials

Annual	2023
Revenue:	$11.76M
Gross Profit:	$6.30M (53.61 %)
EPS:	$-3.12

Q4	2023
Revenue:	$5.14M
Gross Profit:	$3.63M (70.51 %)
EPS:	$-0.690

Q3	2023
Revenue:	$3.12M
Gross Profit:	$-82 000.00 (-2.63 %)
EPS:	$-0.720

Q2	2023
Revenue:	$2.09M
Gross Profit:	$-933 000 (-44.58 %)
EPS:	$-0.870

Financial Reports:

No articles found.

Verve Therapeutics, Inc.

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.